MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Balance Sheet History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
EQUITY AND LIABILITIES | |||||
Share Capital | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
Equity - Authorised | ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr |
Equity - Issued | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
Equity Paid Up | ₹45 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr | ₹41 Cr |
Equity Shares Forfeited | - | - | - | - | - |
Adjustments to Equity | - | - | - | - | - |
Preference Capital Paid Up | - | - | - | - | - |
Face Value | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 | ₹1.00 |
Share Warrants & Outstandings | - | ₹93 Cr | - | - | - |
Total Reserves | ₹1,700 Cr | ₹1,068 Cr | ₹846 Cr | ₹595 Cr | ₹502 Cr |
Securities Premium | ₹504 Cr | ₹173 Cr | ₹175 Cr | ₹175 Cr | ₹175 Cr |
Capital Reserves | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr | ₹0.01 Cr |
Profit & Loss Account Balance | ₹778 Cr | ₹509 Cr | ₹335 Cr | ₹85 Cr | ₹2.98 Cr |
General Reserves | ₹314 Cr | ₹314 Cr | ₹314 Cr | ₹314 Cr | ₹314 Cr |
Other Reserves | ₹104 Cr | ₹72 Cr | ₹22 Cr | ₹21 Cr | ₹9.69 Cr |
Reserve excluding Revaluation Reserve | ₹1,700 Cr | ₹1,068 Cr | ₹846 Cr | ₹595 Cr | ₹502 Cr |
Revaluation reserve | - | - | - | - | - |
Shareholder's Funds | ₹1,745 Cr | ₹1,202 Cr | ₹886 Cr | ₹636 Cr | ₹542 Cr |
Minority Interest | ₹20 Cr | ₹21 Cr | ₹19 Cr | ₹13 Cr | ₹10 Cr |
Long-Term Borrowings | - | - | - | - | - |
Secured Loans | - | - | - | - | - |
Non Convertible Debentures | - | - | - | - | - |
Converible Debentures & Bonds | - | - | - | - | - |
Packing Credit - Bank | - | - | - | - | - |
Inter Corporate & Security Deposit | - | - | - | - | - |
Term Loans - Banks | - | - | - | - | - |
Term Loans - Institutions | - | - | - | - | - |
Other Secured | - | - | - | - | - |
Unsecured Loans | - | - | - | - | - |
Fixed Deposits - Public | - | - | - | - | - |
Loans and advances from subsidiaries | - | - | - | - | - |
Inter Corporate Deposits (Unsecured) | - | - | - | - | - |
Foreign Currency Convertible Notes | - | - | - | - | - |
Long Term Loan in Foreign Currency | - | - | - | - | - |
Loans - Banks | - | - | - | - | - |
Loans - Govt. | - | - | - | - | - |
Loans - Others | - | - | - | - | - |
Other Unsecured Loan | - | - | - | - | - |
Deferred Tax Assets / Liabilities | ₹15 Cr | ₹14 Cr | ₹7.26 Cr | ₹10 Cr | ₹5.78 Cr |
Deferred Tax Assets | ₹12 Cr | ₹9.16 Cr | ₹2.09 Cr | ₹3.20 Cr | ₹2.78 Cr |
Deferred Tax Liability | ₹27 Cr | ₹23 Cr | ₹9.35 Cr | ₹13 Cr | ₹8.56 Cr |
Other Long Term Liabilities | ₹66 Cr | ₹41 Cr | ₹14 Cr | ₹13 Cr | ₹10.00 Cr |
Long Term Trade Payables | - | - | - | - | - |
Long Term Provisions | ₹13 Cr | ₹1.86 Cr | ₹2.11 Cr | ₹1.48 Cr | ₹1.36 Cr |
Total Non-Current Liabilities | ₹94 Cr | ₹57 Cr | ₹24 Cr | ₹24 Cr | ₹17 Cr |
Current Liabilities | - | - | - | - | - |
Trade Payables | ₹231 Cr | ₹200 Cr | ₹169 Cr | ₹110 Cr | ₹106 Cr |
Sundry Creditors | ₹231 Cr | ₹200 Cr | ₹169 Cr | ₹110 Cr | ₹106 Cr |
Acceptances | - | - | - | - | - |
Due to Subsidiaries- Trade Payables | - | - | - | - | - |
Other Current Liabilities | ₹42 Cr | ₹97 Cr | ₹80 Cr | ₹59 Cr | ₹21 Cr |
Bank Overdraft / Short term credit | - | - | - | - | - |
Advances received from customers | ₹0.91 Cr | ₹1.74 Cr | ₹0.57 Cr | - | - |
Interest Accrued But Not Due | - | - | - | - | - |
Share Application Money | - | - | - | - | - |
Current maturity of Debentures & Bonds | - | - | - | - | - |
Current maturity - Others | - | - | - | - | - |
Other Liabilities | ₹41 Cr | ₹95 Cr | ₹79 Cr | ₹59 Cr | ₹21 Cr |
Short Term Borrowings | ₹42 Cr | ₹41 Cr | ₹19 Cr | ₹19 Cr | ₹100 Cr |
Secured ST Loans repayable on Demands | ₹42 Cr | ₹41 Cr | ₹19 Cr | ₹19 Cr | ₹100 Cr |
Working Capital Loans- Sec | ₹42 Cr | ₹36 Cr | ₹19 Cr | ₹19 Cr | ₹100 Cr |
Buyers Credits - Unsec | - | - | - | - | - |
Commercial Borrowings- Unsec | - | - | - | - | - |
Other Unsecured Loans | ₹-42 Cr | ₹-36 Cr | ₹-19 Cr | ₹-19 Cr | ₹-100 Cr |
Short Term Provisions | ₹51 Cr | ₹42 Cr | ₹32 Cr | ₹41 Cr | ₹5.74 Cr |
Proposed Equity Dividend | - | - | - | ₹27 Cr | - |
Provision for Corporate Dividend Tax | - | - | - | - | - |
Provision for Tax | ₹50 Cr | ₹41 Cr | ₹30 Cr | ₹12 Cr | ₹4.90 Cr |
Provision for post retirement benefits | - | - | - | - | - |
Preference Dividend | - | - | - | - | - |
Other Provisions | ₹1.33 Cr | ₹0.72 Cr | ₹1.86 Cr | ₹1.76 Cr | ₹0.84 Cr |
Total Current Liabilities | ₹365 Cr | ₹380 Cr | ₹299 Cr | ₹229 Cr | ₹233 Cr |
Total Liabilities | ₹2,224 Cr | ₹1,660 Cr | ₹1,228 Cr | ₹902 Cr | ₹802 Cr |
ASSETS | |||||
Gross Block | ₹828 Cr | ₹726 Cr | ₹552 Cr | ₹565 Cr | ₹506 Cr |
Less: Accumulated Depreciation | ₹342 Cr | ₹298 Cr | ₹243 Cr | ₹263 Cr | ₹237 Cr |
Less: Impairment of Assets | - | - | - | - | - |
Net Block | ₹486 Cr | ₹428 Cr | ₹309 Cr | ₹303 Cr | ₹270 Cr |
Lease Adjustment A/c | - | - | - | - | - |
Capital Work in Progress | ₹7.25 Cr | ₹0.70 Cr | ₹5.60 Cr | - | - |
Non Current Investments | - | - | - | - | - |
Long Term Investment | - | - | - | - | - |
Quoted | - | - | - | - | - |
Unquoted | - | - | - | - | - |
Long Term Loans & Advances | ₹28 Cr | ₹4.16 Cr | ₹4.16 Cr | ₹5.73 Cr | ₹1.29 Cr |
Other Non Current Assets | - | - | - | - | - |
Total Non-Current Assets | ₹525 Cr | ₹435 Cr | ₹325 Cr | ₹308 Cr | ₹271 Cr |
Current Assets Loans & Advances | - | - | - | - | - |
Currents Investments | ₹0.54 Cr | ₹0.44 Cr | ₹0.26 Cr | - | - |
Quoted | ₹0.54 Cr | ₹0.44 Cr | ₹0.26 Cr | - | - |
Unquoted | - | - | - | - | - |
Inventories | ₹485 Cr | ₹424 Cr | ₹404 Cr | ₹242 Cr | ₹293 Cr |
Raw Materials | ₹203 Cr | ₹151 Cr | ₹118 Cr | ₹92 Cr | ₹90 Cr |
Work-in Progress | ₹20 Cr | ₹11 Cr | ₹15 Cr | ₹16 Cr | ₹13 Cr |
Finished Goods | ₹135 Cr | ₹134 Cr | ₹176 Cr | ₹92 Cr | ₹123 Cr |
Packing Materials | - | - | - | - | - |
Stores Ā and Spare | - | - | - | - | - |
Other Inventory | ₹127 Cr | ₹128 Cr | ₹96 Cr | ₹43 Cr | ₹67 Cr |
Sundry Debtors | ₹417 Cr | ₹395 Cr | ₹272 Cr | ₹243 Cr | ₹177 Cr |
Debtors more than Six months | ₹6.10 Cr | ₹21 Cr | ₹1.97 Cr | - | - |
Debtors Others | ₹414 Cr | ₹373 Cr | ₹270 Cr | ₹243 Cr | ₹177 Cr |
Cash and Bank | ₹715 Cr | ₹349 Cr | ₹212 Cr | ₹94 Cr | ₹34 Cr |
Cash in hand | ₹0.02 Cr | ₹0.03 Cr | ₹0.04 Cr | ₹0.04 Cr | ₹0.04 Cr |
Balances at Bank | ₹715 Cr | ₹349 Cr | ₹212 Cr | ₹94 Cr | ₹33 Cr |
Other cash and bank balances | - | - | - | - | - |
Other Current Assets | ₹23 Cr | ₹24 Cr | ₹13 Cr | ₹11 Cr | ₹28 Cr |
Interest accrued on Investments | ₹2.93 Cr | ₹1.32 Cr | ₹0.10 Cr | - | - |
Interest accrued on Debentures | - | - | - | - | - |
Deposits with Government | - | - | - | - | - |
Interest accrued and or due on loans | - | - | - | - | - |
Prepaid Expenses | ₹20 Cr | ₹16 Cr | - | - | - |
Other current_assets | ₹0.72 Cr | ₹7.06 Cr | ₹13 Cr | ₹11 Cr | ₹28 Cr |
Short Term Loans and Advances | ₹59 Cr | ₹32 Cr | ₹0.98 Cr | ₹3.40 Cr | - |
Advances recoverable in cash or in kind | ₹7.48 Cr | ₹4.87 Cr | ₹0.98 Cr | ₹3.40 Cr | - |
Advance income tax and TDS | ₹26 Cr | ₹27 Cr | - | - | - |
Amounts due from directors | - | - | - | - | - |
Due From Subsidiaries | - | - | - | - | - |
Inter corporate deposits | - | - | - | - | - |
Corporate Deposits | - | - | - | - | - |
Other Loans & Advances | ₹25 Cr | - | - | - | - |
Total Current Assets | ₹1,700 Cr | ₹1,225 Cr | ₹903 Cr | ₹594 Cr | ₹531 Cr |
Net Current Assets (Including Current Investments) | ₹1,334 Cr | ₹845 Cr | ₹604 Cr | ₹365 Cr | ₹299 Cr |
Miscellaneous Expenses not written off | - | - | - | - | - |
Total Assets | ₹2,224 Cr | ₹1,660 Cr | ₹1,228 Cr | ₹902 Cr | ₹802 Cr |
Contingent Liabilities | ₹1.45 Cr | ₹1.45 Cr | ₹20 Cr | ₹48 Cr | ₹30 Cr |
Total Debt | ₹42 Cr | ₹41 Cr | ₹19 Cr | ₹19 Cr | ₹100 Cr |
Book Value | 38.51 | 27.10 | 21.66 | 15.54 | 13.25 |
Adjusted Book Value | 38.51 | 27.10 | 21.66 | 15.54 | 13.25 |
Compare Balance Sheet of peers of MARKSANS PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MARKSANS PHARMA | ₹7,607.0 Cr | 2% | -8.9% | 109.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics |
MARKSANS PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MARKSANS PHARMA | 2% |
-8.9% |
109.1% |
SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses